Myeloid cell heterogeneity in lung cancer: implication for immunotherapy

被引:15
|
作者
Sangaletti, Sabina [1 ]
Ferrara, Roberto [2 ]
Tripodo, Claudio [3 ,4 ]
Garassino, Marina Chiara [2 ]
Colombo, Mario Paolo [1 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Mol Immunol Unit, Dept Res, Via Amadeo 42, I-20133 Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] Univ Palermo, Tumor Immunol Unit, Palermo, Italy
[4] FIRC Inst Mol Oncol IFOM, Milan, Italy
关键词
Lung cancer; Myeloid cells; DNA-based traps; Immunotherapy; NEUTROPHIL EXTRACELLULAR TRAPS; CIRCULATING TUMOR-CELLS; TO-LYMPHOCYTE RATIO; PERIPHERAL-BLOOD; SUPPRESSOR-CELLS; DENDRITIC CELLS; OUTCOMES; MARKER; SUBPOPULATIONS; LEUKOCYTOSIS;
D O I
10.1007/s00262-021-02916-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung is a specialized tissue where metastases from primary lung tumors takeoff and those originating from extra-pulmonary sites land. One commonality characterizing these processes is the supportive role exerted by myeloid cells, particularly neutrophils, whose recruitment is facilitated in this tissue microenvironment. Indeed, neutrophils have important part in the pathophysiology of this organ and the key mechanisms regulating neutrophil expansion and recruitment during infection can be co-opted by tumor cells to promote growth and metastasis. Although neutrophils dominate the myeloid landscape of lung cancer other populations including macrophages, dendritic cells, mast cells, basophils and eosinophils contribute to the complexity of lung cancer TME. In this review, we discuss the origin and significance of myeloid cells heterogeneity in lung cancer, which translates not only in a different frequency of immune populations but it encompasses state of activation, morphology, localization and mutual interactions. The relevance of such heterogeneity is considered in the context of tumor growth and response to immunotherapy.
引用
收藏
页码:2429 / 2438
页数:10
相关论文
共 50 条
  • [21] Immunotherapy for lung cancer
    Bradbury, Penelope A.
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S164 - S170
  • [22] Immunotherapy for lung cancer
    Sathish, Girshani
    Monavarshini, L. K.
    Sundaram, Keerthi
    Subramanian, Sendilvelan
    Kannayiram, Gomathi
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 254
  • [23] Immunotherapy for Lung Cancer
    Reinmuth, Niels
    Reck, Martin
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (06) : 360 - 368
  • [24] Immunotherapy in lung cancer
    Villaruz, Liza C.
    Kalyan, Aparna
    Zarour, Hassane
    Socinski, Mark A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (01) : 2 - 14
  • [25] Immunotherapy in lung cancer
    Al-Moundhri, M
    O'Brien', M
    Souberbielle, BE
    BRITISH JOURNAL OF CANCER, 1998, 78 (03) : 282 - 288
  • [26] Immunotherapy for lung cancer
    Steven, Antonius
    Fisher, Scott A.
    Robinson, Bruce W.
    RESPIROLOGY, 2016, 21 (05) : 821 - 833
  • [27] Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer
    Rice, Shawn J.
    Belani, Chandra P.
    PLOS ONE, 2021, 16 (12):
  • [28] Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
    Li, Shumin
    Zhang, Chengyan
    Pang, Guanchao
    Wang, Pingli
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [29] Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities
    Ilie, M.
    Benzaquen, J.
    Hofman, V.
    Lassalle, S.
    Yazbeck, N.
    Leroy, S.
    Heeke, S.
    Bence, C.
    Mograbi, B.
    Glaichenhaus, N.
    Marquette, C. -H.
    Hofman, P.
    CURRENT MOLECULAR MEDICINE, 2017, 17 (08) : 527 - 540
  • [30] T-cell-associated cellular immunotherapy for lung cancer
    Li, Ke
    Zhang, Qing
    Zhang, Yang
    Yang, Jie
    Zheng, Junnian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (07) : 1249 - 1258